For type 2 diabetes mellitus. ANDA 91664, held by Lupin. Metformin Hydrochloride.
As of Nov 16, 2026, ANDA 91664 (Metformin Hydrochloride), held by Lupin, was first approved by FDA on Jul 19, 2013, with 2 approved supplements and 0 published complete response letters.
Metformin hydrochloride extended-release tablet is a biguanide indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 19, 2013 | Original application | Approved |
| Metformin Hydrochloride500MG · tablet, extended release;oral | Metformin Hydrochloride | Rx |
| Metformin Hydrochloride1GM · tablet, extended release;oral | Metformin Hydrochloride | Rx |
| Sep 5, 2019 | Supplement 2Labeling · Standard review | Approved | None posted |
| Sep 5, 2019 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jul 19, 2013 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters